0001209191-23-035733.txt : 20230609
0001209191-23-035733.hdr.sgml : 20230609
20230609160408
ACCESSION NUMBER: 0001209191-23-035733
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230607
FILED AS OF DATE: 20230609
DATE AS OF CHANGE: 20230609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scheiner Zachary
CENTRAL INDEX KEY: 0001816523
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39370
FILM NUMBER: 231005186
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 18TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nkarta, Inc.
CENTRAL INDEX KEY: 0001787400
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474515206
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6000 SHORELINE COURT
STREET 2: SUITE 102
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-582-4923
MAIL ADDRESS:
STREET 1: 6000 SHORELINE COURT
STREET 2: SUITE 102
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-07
0
0001787400
Nkarta, Inc.
NKTX
0001816523
Scheiner Zachary
C/O RA CAPITAL MANAGEMENT
200 BERKELEY STREET, 18TH FLOOR
BOSTON
MA
02116
1
0
0
0
0
Stock Option (right to buy)
4.86
2023-06-07
4
A
0
22500
0.00
A
2033-06-06
Common Stock
22500
22500
D
All shares subject to the option vest 100% on the first to occur of (i) June 7, 2024 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement).
Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.
/s/ Alicia Hager, as Attorney-in-Fact
2023-06-09